FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115257679> ?p ?o ?g. }

• W2115257679 endingPage "1222" @default.
• W2115257679 startingPage "1214" @default.
• W2115257679 abstract "BACKGROUND The role of non-complement activating antibodies (ncAbs) to mismatched donor human leukocyte antigen (HLA) in the pathogenesis of chronic lung rejection is not known. We used a murine model of obliterative airway disease (OAD) induced by Abs to major histocompatibility major histocompatibility complex (MHC) class I and serum from donor-specific Abs developed in human lung transplant (LTx) recipients to test the role of ncAbs in the development of OAD and bronchiolitis obliterans syndrome (BOS). METHODS Anti-MHC ncAbs were administered intrabronchially in B.10 mice or in C3 knockout (C3KO) mice. Lungs were analyzed by histopathology. Lymphocytes secreting interleukin (IL)-17, interferon-γ, or IL-10 to collagen V and K-α1 tubulin (Kα1T) were enumerated by enzyme-linked immunospot assay. Serum antibodies to collagen V and Kα1T were determined by enzyme-linked immunosorbent assay. Cytokine and growth factor expression in lungs was determined by real-time polymerase chain reaction. Donor-specific Abs from patients with BOS and control BOS-negative LTx recipients were analyzed by C1q assay. RESULTS Administration of ncAbs in B.10 mice or C3KO resulted in OAD lesions. There were significant increases in IL-17– and interferon-γ–secreting cells to collagen V and Kα1T, along with serum Abs to these antigens. There was also augmented expression of monocyte chemotactic protein-1, IL-6, IL-1β, vascular endothelial growth factor, transforming growth factor-β, and fibroblastic growth factor in mice administered ncAbs by Day 3. Among 5 LTx recipients with BOS, only 1 had C1q binding donor-specific Abs. CONCLUSION Complement activation by Abs to MHC class I is not required for development of OAD and human BOS. Therefore, anti-MHC binding to epithelial and endothelial cells can directly activate pro-fibrotic and pro-inflammatory cascades leading to immune response to self-antigens and chronic rejection. The role of non-complement activating antibodies (ncAbs) to mismatched donor human leukocyte antigen (HLA) in the pathogenesis of chronic lung rejection is not known. We used a murine model of obliterative airway disease (OAD) induced by Abs to major histocompatibility major histocompatibility complex (MHC) class I and serum from donor-specific Abs developed in human lung transplant (LTx) recipients to test the role of ncAbs in the development of OAD and bronchiolitis obliterans syndrome (BOS). Anti-MHC ncAbs were administered intrabronchially in B.10 mice or in C3 knockout (C3KO) mice. Lungs were analyzed by histopathology. Lymphocytes secreting interleukin (IL)-17, interferon-γ, or IL-10 to collagen V and K-α1 tubulin (Kα1T) were enumerated by enzyme-linked immunospot assay. Serum antibodies to collagen V and Kα1T were determined by enzyme-linked immunosorbent assay. Cytokine and growth factor expression in lungs was determined by real-time polymerase chain reaction. Donor-specific Abs from patients with BOS and control BOS-negative LTx recipients were analyzed by C1q assay. Administration of ncAbs in B.10 mice or C3KO resulted in OAD lesions. There were significant increases in IL-17– and interferon-γ–secreting cells to collagen V and Kα1T, along with serum Abs to these antigens. There was also augmented expression of monocyte chemotactic protein-1, IL-6, IL-1β, vascular endothelial growth factor, transforming growth factor-β, and fibroblastic growth factor in mice administered ncAbs by Day 3. Among 5 LTx recipients with BOS, only 1 had C1q binding donor-specific Abs. Complement activation by Abs to MHC class I is not required for development of OAD and human BOS. Therefore, anti-MHC binding to epithelial and endothelial cells can directly activate pro-fibrotic and pro-inflammatory cascades leading to immune response to self-antigens and chronic rejection." @default.
• W2115257679 created "2016-06-24" @default.
• W2115257679 creator A5002306119 @default.
• W2115257679 creator A5014718746 @default.
• W2115257679 creator A5028436053 @default.
• W2115257679 creator A5048361872 @default.
• W2115257679 creator A5057225912 @default.
• W2115257679 creator A5064875263 @default.
• W2115257679 creator A5065986871 @default.
• W2115257679 creator A5084105733 @default.
• W2115257679 creator A5087757869 @default.
• W2115257679 creator A5089421747 @default.
• W2115257679 date "2012-11-01" @default.
• W2115257679 modified "2023-09-25" @default.
• W2115257679 title "Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection" @default.
• W2115257679 cites W1505723685 @default.
• W2115257679 cites W1562045719 @default.
• W2115257679 cites W1572575341 @default.
• W2115257679 cites W1602738207 @default.
• W2115257679 cites W1623169079 @default.
• W2115257679 cites W1905089855 @default.
• W2115257679 cites W1952464140 @default.
• W2115257679 cites W1969401037 @default.
• W2115257679 cites W1980529703 @default.
• W2115257679 cites W1984483047 @default.
• W2115257679 cites W1993505554 @default.
• W2115257679 cites W2002272822 @default.
• W2115257679 cites W2006323392 @default.
• W2115257679 cites W2018043519 @default.
• W2115257679 cites W2021165722 @default.
• W2115257679 cites W2023720635 @default.
• W2115257679 cites W2023919621 @default.
• W2115257679 cites W2028327623 @default.
• W2115257679 cites W2051785580 @default.
• W2115257679 cites W2064713624 @default.
• W2115257679 cites W2069288346 @default.
• W2115257679 cites W2075033611 @default.
• W2115257679 cites W2075805721 @default.
• W2115257679 cites W2077249413 @default.
• W2115257679 cites W2088810713 @default.
• W2115257679 cites W2091515846 @default.
• W2115257679 cites W2093726237 @default.
• W2115257679 cites W2112249032 @default.
• W2115257679 cites W2126010472 @default.
• W2115257679 cites W2136040035 @default.
• W2115257679 cites W2167028678 @default.
• W2115257679 cites W2333121623 @default.
• W2115257679 cites W2468326825 @default.
• W2115257679 doi "https://doi.org/10.1016/j.healun.2012.08.011" @default.
• W2115257679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3472127" @default.
• W2115257679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22980951" @default.
• W2115257679 hasPublicationYear "2012" @default.
• W2115257679 type Work @default.
• W2115257679 sameAs 2115257679 @default.
• W2115257679 citedByCount "8" @default.
• W2115257679 countsByYear W21152576792013 @default.
• W2115257679 countsByYear W21152576792014 @default.
• W2115257679 countsByYear W21152576792015 @default.
• W2115257679 countsByYear W21152576792016 @default.
• W2115257679 countsByYear W21152576792018 @default.
• W2115257679 countsByYear W21152576792019 @default.
• W2115257679 countsByYear W21152576792023 @default.
• W2115257679 crossrefType "journal-article" @default.
• W2115257679 hasAuthorship W2115257679A5002306119 @default.
• W2115257679 hasAuthorship W2115257679A5014718746 @default.
• W2115257679 hasAuthorship W2115257679A5028436053 @default.
• W2115257679 hasAuthorship W2115257679A5048361872 @default.
• W2115257679 hasAuthorship W2115257679A5057225912 @default.
• W2115257679 hasAuthorship W2115257679A5064875263 @default.
• W2115257679 hasAuthorship W2115257679A5065986871 @default.
• W2115257679 hasAuthorship W2115257679A5084105733 @default.
• W2115257679 hasAuthorship W2115257679A5087757869 @default.
• W2115257679 hasAuthorship W2115257679A5089421747 @default.
• W2115257679 hasBestOaLocation W21152576792 @default.
• W2115257679 hasConcept C126322002 @default.
• W2115257679 hasConcept C147483822 @default.
• W2115257679 hasConcept C159654299 @default.
• W2115257679 hasConcept C203014093 @default.
• W2115257679 hasConcept C207936829 @default.
• W2115257679 hasConcept C2776180460 @default.
• W2115257679 hasConcept C2776739411 @default.
• W2115257679 hasConcept C2777714996 @default.
• W2115257679 hasConcept C2778690821 @default.
• W2115257679 hasConcept C2780841837 @default.
• W2115257679 hasConcept C2780942790 @default.
• W2115257679 hasConcept C2781448352 @default.
• W2115257679 hasConcept C71924100 @default.
• W2115257679 hasConceptScore W2115257679C126322002 @default.
• W2115257679 hasConceptScore W2115257679C147483822 @default.
• W2115257679 hasConceptScore W2115257679C159654299 @default.
• W2115257679 hasConceptScore W2115257679C203014093 @default.
• W2115257679 hasConceptScore W2115257679C207936829 @default.
• W2115257679 hasConceptScore W2115257679C2776180460 @default.
• W2115257679 hasConceptScore W2115257679C2776739411 @default.
• W2115257679 hasConceptScore W2115257679C2777714996 @default.
• W2115257679 hasConceptScore W2115257679C2778690821 @default.
• W2115257679 hasConceptScore W2115257679C2780841837 @default.
• W2115257679 hasConceptScore W2115257679C2780942790 @default.

• next